tiprankstipranks
Organicell Regenerative Medicine (OCEL)
OTHER OTC:OCEL
US Market

Organicell Regenerative Medicine (OCEL) Financial Statements

40 Followers

Organicell Regenerative Medicine Financial Overview

Organicell Regenerative Medicine's market cap is currently ―. The company's EPS TTM is $-0.978; its P/E ratio is -2.80; Organicell Regenerative Medicine is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Oct 23Jul 23Apr 23Jan 23Oct 22
Income Statement-
Total Revenue$ 1.42M$ 1.22M$ 845.50K$ 1.07M$ 1.44M
Gross Profit$ 1.29M$ 1.22M$ 737.42K$ 965.91K$ 1.17M
EBIT$ -851.60K$ -1.28M$ -1.91M$ -2.23M$ -2.94M
EBITDA$ -768.86K$ -972.10K$ -1.66M$ -2.03M$ -2.68M
Net Income Common Stockholders$ -1.09M$ -1.62M$ -1.99M$ -2.29M$ -3.02M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.76M$ 633.58K$ 1.13M$ 1.42M$ 3.75M
Total Assets$ 2.78M$ 2.46M$ 3.33M$ 4.32M$ 6.20M
Total Debt$ 36.24K$ 634.51K$ 501.38K$ 423.49K$ 1.04M
Net Debt$ -1.72M$ 925.00$ -629.56K$ -999.01K$ -2.71M
Total Liabilities$ 4.02M$ 3.48M$ 3.47M$ 3.64M$ 4.31M
Stockholders Equity$ -1.24M$ -1.02M$ -138.91K$ 677.01K$ 1.89M
Cash Flow-
Free Cash Flow$ 955.67K$ -467.69K$ -670.85K$ -1.30M$ -2.07M
Operating Cash Flow$ 220.45K$ -464.15K$ -670.85K$ -1.28M$ -1.76M
Investing Cash Flow$ 735.22K$ -3.54K$ -100.00K$ -16.12K$ -308.22K
Financing Cash Flow$ 166.95K$ -29.66K$ 479.29K$ -1.03M$ 5.74M
Currency in USD

Organicell Regenerative Medicine Earnings and Revenue History

Organicell Regenerative Medicine Debt to Assets

Organicell Regenerative Medicine Cash Flow

Organicell Regenerative Medicine Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis